Navigation Links
Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
Date:9/1/2009

BASEL and REINACH, Switzerland, September 2 /PRNewswire/ --

- CAPRA-2-Data Will be Used to File for US Marketing Approval

Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM).

The CAPRA-2 study (Circadian Administration of Prednisone in Rheumatoid Arthritis-2) was a 12-week, multicentre, double-blind phase III trial evaluating the safety and efficacy of Lodotra(TM) for the treatment of rheumatoid arthritis ("RA"), a chronic, progressive and disabling autoimmune disorder. In total 350 patients, all inadequate responders to DMARD therapy, were randomised in one of two arms to receive either Lodotra(TM) (5mg once daily), or placebo in addition to their existing therapy. The primary efficacy endpoint was the ACR-20 response rate, which is defined as at least a 20% improvement in a number of disease-specific criteria. The key secondary endpoint was the change in the duration of morning stiffness of the joints. CAPRA-2-data will be used to file for US marketing approval with the FDA together with the data already available from the CAPRA-1 pivotal phase III trial which has shown the superiority of Lodotra(TM) over standard prednisone treatment.

Lodotra(TM)-treated patients showed an ACR-20 response of 49% compared to 29% in the placebo group. The difference was highly significant (p=0.0002; LOCF). The reduction of morning stiffness was 44% in the Lodotra(TM) group (21 % in the placebo group). This difference was also highly significant (p=0.0008). Lodotra(TM) was safe and well tolerated. The number of adverse events was low and comparable in both groups.

Dr. Anders Harfstrand, CEO of Nitec commented: "We are deli
'/>"/>

SOURCE Nitec Pharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
2. Benitec MOU With CalbaTech, Inc.
3. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
4. Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009
5. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
6. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
7. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
8. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
9. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
10. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
11. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Formex, ... manufacturing, announced that Mr. Greg Weilersbacher joined Formex ... 25, 2014. Greg Weilersbacher ... experience with focused expertise in Quality Assurance, ... Mr. Weilersbacher brings to Formex a ...
(Date:9/16/2014)... , Sept. 16, 2014 On September 25 ... exhibition focusing on medical design and manufacturing - MEDTEC ... Shanghai World Expo Exhibition & Convention Center, bringing together ... and regions to showcase their latest medical-grade raw materials, ... only one week remaining for free visitor pre-registration to ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... Mylan Inc. (Nasdaq: MYL ) today announced ... from the U.S. Food and Drug Administration (FDA) for ... Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg. , ... Bristol Myers Squibb,s Parkinson,s treatment Sinemet®, 10mg/100mg, 25mg/100mg and ...
... JERUSALEM, Israel, September 30 Gamida Cell ... generic,name of what is widely known as "StemEx", as ... The article, carlecortemcel-l, an ex vivo expanded,umbilical cord blood ... Chan and Dr. Demetrios Petropoulos, will be published in ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/16/2014)... who received hypofractionated (HPFX) radiation therapy (RT) reported ... bladder and bowel function were at similar levels ... today at the American Society for Radiation Oncology,s ... parallel quality of life outcomes occurred between groups ... RT. , The phase I/II trial enrolled 343 ...
(Date:9/16/2014)... (parous women) appear to have an increased risk ... that carries a higher mortality rate and is ... A similar relationship was found for triple-negative breast ... risk of estrogen receptor-negative and triple-negative breast cancer ... never breastfed. These findings, published in the ...
(Date:9/16/2014)... of getting prostate cancer after a worldwide team of ... genetic biomarkers, reported in Nature Genetics today. ... Jyotsna Batra and Distinguished Professor Judith Clements, who led ... hubs around the world, said the teams analysed more ... "It,s the largest analysis of genetic biomarkers ever done. ...
(Date:9/16/2014)... 16, 2014 Definitive Healthcare ... and healthcare providers, is pleased to announce the ... online database, now available for subscription, features detailed ... health system affiliations. , The Canadian database spans ... intelligence on over 750 hospitals. Each hospital ...
(Date:9/16/2014)... 16, 2014 Gary F. Locke, the ... has selected Worldwide Speakers Group for exclusive representation of ... of Commerce and Governor of Washington, Locke is widely ... U.S.-China relations, global expansion, and business growth. , “Gary ... and how to grow an organization’s global presence in ...
Breaking Medicine News(10 mins):Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 2Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 3Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Canadian Hospital Database Now Offered by Definitive Healthcare 2Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2
... by day. The number of infections a person has been ... death from heart attack. It is long been suspected that ... This has been possible by promoting inflammation within the coronary ... have conflicting evidence. ,According to researchers at University ...
... (Dietary Approaches to Stop Hypertension) says by reducing salt ... effective in decreasing blood pressure as antihypertensive medications.In addition, ... decrease in the prevalence of heart disease and a ... ,The DASH-Sodium study included 342 people. More than half ...
... to a new study the use of serotonin-raising drugs ... a stroke. In common the mecahnism of durgs is ... with many different roles in the body.// Examples include ... antidepressants. ,Researchers at the Health welfare hospital, ...
... of the American Chemical Society indicated that cooking vegetables ... our body can absorb from them.// Tung-Ching Lee, a food ... vegetables and found that 25 of them benefited from cooking ... iron content in the vegetable is the same before and ...
... amount of fruit and vegetables, but they are still only a ... a booster to our human system.On an average the percentage of ... increased from 15 per cent to18 per cent between 1993 and ... ,Among women, the percentage increase was from 20 per cent to ...
... impairment. A new hearing device that is implanted in the ... aid. Doctors say that there's now a better option for ... sound through the eardrum, and may produce feedback - distracting ... the feeling of talking within a barrel. ,The ...
Cached Medicine News:
... three-dimensional VCS technology, providing ... efficiency in white cell ... With its reputation for ... is an affordable solution ...
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL....
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
Medicine Products: